| Dr Leonard J Leone, DO | |
|
2315 Myrtle St Ste L90, Erie, PA 16502-4607 | |
| (814) 452-7575 | |
| (814) 452-7574 |
| Full Name | Dr Leonard J Leone |
|---|---|
| Gender | Male |
| Speciality | Psychiatry & Neurology - Neurology |
| Location | 2315 Myrtle St Ste L90, Erie, Pennsylvania |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043205214 | NPI | - | NPPES |
| 001547528 | Medicaid | PA | |
| 11125127 | Other | CAQH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | OS-008832-L (Pennsylvania) | Primary |
| Entity Name | Allegheny Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073081493 PECOS PAC ID: 5395649586 Enrollment ID: O20040310000602 |
News Archive
Amira Pharmaceuticals, Inc. announced today that it will present preclinical and clinical data from its DP2 receptor antagonist program on December 17, 2010, at Pacifichem 2010 in Honolulu, Hawaii. The data from Amira's clinical-stage DP2 program will be delivered by Brian Stearns, Ph.D., in a presentation titled "Discovery and optimization of a novel series of DP2 antagonists with efficacy in mouse models of COPD and asthma."
Sistemic Ltd., the recent winners of the coveted Most Promising Life Science Company by Nexxus, today announced the launch of their SistemTOX™ early predictive and investigative drug toxicity screening service. Based on world-leading Scottish microRNA research and technology, SistemTOX™ filters out potentially harmful compounds early in the development process, helping to save millions of pounds in costs.
Need another reason to eat your vegetables? New research shows that some of them contain chemicals that appear to enhance DNA repair in cells, which could lead to protection against cancer development, say Georgetown University Medical Center researchers.
Five- and 10-year survival rates for patients with non-Hodgkin lymphoma appear to have increased from the 1990s to the early 21st century, according to a report in the March 10 issue of Archives of Internal Medicine.
Abraxis BioScience, Inc., a fully integrated biotechnology company, today announced that the Office of Orphan Products Development of the Food and Drug Administration (FDA) has granted orphan drug designation to the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the treatment of pancreatic cancer as well as stage IIB-IV melanoma.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Leonard J Leone, DO 2315 Myrtle St Ste L90, Erie, PA 16502-4607 Ph: (814) 452-7575 | Dr Leonard J Leone, DO 2315 Myrtle St Ste L90, Erie, PA 16502-4607 Ph: (814) 452-7575 |
News Archive
Amira Pharmaceuticals, Inc. announced today that it will present preclinical and clinical data from its DP2 receptor antagonist program on December 17, 2010, at Pacifichem 2010 in Honolulu, Hawaii. The data from Amira's clinical-stage DP2 program will be delivered by Brian Stearns, Ph.D., in a presentation titled "Discovery and optimization of a novel series of DP2 antagonists with efficacy in mouse models of COPD and asthma."
Sistemic Ltd., the recent winners of the coveted Most Promising Life Science Company by Nexxus, today announced the launch of their SistemTOX™ early predictive and investigative drug toxicity screening service. Based on world-leading Scottish microRNA research and technology, SistemTOX™ filters out potentially harmful compounds early in the development process, helping to save millions of pounds in costs.
Need another reason to eat your vegetables? New research shows that some of them contain chemicals that appear to enhance DNA repair in cells, which could lead to protection against cancer development, say Georgetown University Medical Center researchers.
Five- and 10-year survival rates for patients with non-Hodgkin lymphoma appear to have increased from the 1990s to the early 21st century, according to a report in the March 10 issue of Archives of Internal Medicine.
Abraxis BioScience, Inc., a fully integrated biotechnology company, today announced that the Office of Orphan Products Development of the Food and Drug Administration (FDA) has granted orphan drug designation to the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the treatment of pancreatic cancer as well as stage IIB-IV melanoma.
› Verified 3 days ago
Ryan J Lynch, DO Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 5535 Peach St, Erie, PA 16509 Phone: 814-868-3488 Fax: 814-868-3499 | |
Kripa Shankar Singh, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1330 W 26th St, Erie, PA 16508 Phone: 814-459-9300 Fax: 814-454-7780 | |
Sherifia Elaine Heron, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 3216 State St, Erie, PA 16508 Phone: 724-437-0729 | |
Joseph Aaron Holmes, D.O. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 5515 Peach St, Erie, PA 16509 Phone: 181-486-8820 | |
Erica Grazioli, DO Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 120 E 2nd St Third Floor, Erie, PA 16507 Phone: 814-877-8000 Fax: 814-452-2210 | |
G Renee Thomas-clark, DO Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 4740 Peach St, Erie, PA 16509 Phone: 814-454-3174 Fax: 814-616-8002 |